| scholarly article | Q13442814 |
| P50 | author | Hitomi Sezaki | Q92198438 |
| Kenji Ikeda | Q114433562 | ||
| Hiromitsu Kumada | Q114433568 | ||
| Fumitaka Suzuki | Q114923480 | ||
| Masahiro Kobayashi | Q114923755 | ||
| Yoshiyuki Suzuki | Q114923935 | ||
| Yasuji Arase | Q114924322 | ||
| Satoshi Saito | Q114924602 | ||
| Mariko Kobayashi | Q114924823 | ||
| Tetsuya Hosaka | Q56223851 | ||
| Norio Akuta | Q87747459 | ||
| Yusuke Kawamura | Q90407021 | ||
| P2093 | author name string | Taito Fukushima | |
| Tasuku Hara | |||
| P2860 | cites work | Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding | Q27665956 |
| Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis | Q27860811 | ||
| Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis | Q28183279 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing | Q28477175 | ||
| IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Replication of hepatitis C virus | Q29620645 | ||
| Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection | Q29620702 | ||
| Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection | Q30407004 | ||
| Characterization of V36C, a novel amino acid substitution conferring hepatitis C virus (HCV) resistance to telaprevir, a potent peptidomimetic inhibitor of HCV protease | Q33876447 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease | Q34540250 | ||
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
| Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. | Q34638767 | ||
| Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C | Q34671935 | ||
| Use of illumina deep sequencing technology to differentiate hepatitis C virus variants | Q35806939 | ||
| IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C | Q35838595 | ||
| Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information | Q36022991 | ||
| Rapid detection of the ACMG/ACOG-recommended 23 CFTR disease-causing mutations using ion torrent semiconductor sequencing | Q39633738 | ||
| Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy | Q42978970 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. | Q42991231 | ||
| Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. | Q42993815 | ||
| In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. | Q42994273 | ||
| Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. | Q42998703 | ||
| Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo | Q43037298 | ||
| Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
| Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients | Q43039768 | ||
| Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. | Q50650208 | ||
| Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. | Q52909973 | ||
| Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. | Q53460454 | ||
| A high-throughput SNP typing system for genome-wide association studies | Q57269468 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 2862-2868 | |
| P577 | publication date | 2013-06-19 | |
| P1433 | published in | Journal of Clinical Microbiology | Q4041880 |
| P1476 | title | Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1 | |
| P478 | volume | 51 |
| Q43527241 | A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study |
| Q28650908 | Advanced molecular surveillance of hepatitis C virus |
| Q42252352 | Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study |
| Q35641185 | Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus |
| Q41473188 | Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. |
| Q39018557 | HCV inter-subtype 1a/1b recombinant detected by complete-genome next-generation sequencing. |
| Q35870807 | Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. |
| Q35869247 | Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study |
| Q38224436 | Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview |
| Q37654502 | Individualization of chronic hepatitis C treatment according to the host characteristics |
| Q40868771 | No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy |
| Q38885438 | Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review. |
| Q34330704 | Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. |
| Q34983102 | Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients. |
| Q37546699 | Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection |
Search more.